Development and validation of an LC-MS method based on derivatization for quantification of kynurenine pathway metabolites in serum and application in cancer patients.

Authors

Kinga Ożga-Wybranowska, Paweł Stepuch, Inga Łopuszyńska, Marek Durlik, Elżbieta Radzikowska-Büchner, Ryszard Maciejewski, Ilona Sadok

Published in

Journal of chromatography. A. Volume 1785. Pages 467301. Jul 26, 2026. Epub Jul 26, 2026.

Abstract

Simultaneous determination of a broad panel of kynurenine pathway metabolites remains analytically challenging due to their diverse polarity, poor chromatographic retention, and wide concentration range in biological matrices. In this work, a liquid chromatography-mass spectrometry method, which includes a derivatization step to form ester derivatives of tryptophan metabolites, was developed to measure serum levels of kynurenine, kynurenic acid, 3-hydroxykynurenine, picolinic acid, nicotinic acid, quinolinic acid, and xanthurenic acid. Sample preparation procedure was thoroughly optimized. As part of method development, different strategies for sample purification were tested. Ultimately, serum samples after derivatization were subjected to clean-up using solid-phase extraction. This approach enables the separation of isomeric pairs (picolinic and nicotinic acids) and improved the detection of quinolinic acid. Data were normalized to a single internal standard (3-nitro-l-tyrosine), which undergoes derivatization in the same manner as the target analytes. The method demonstrated excellent linearity (R² > 0.99) over wide concentration ranges, typically from low nanomolar to several tens of micromolar levels. Low limits of quantification were determined in a surrogate matrix: 0.35 µM for picolinic acid, 0.11 µM for 3-hydroxykynurenine, and <80 nM for the other metabolites.Inter- and intraday accuracy ranged between 90-110%, with recoveries >70% for all analytes. The method was validated and successfully applied to the quantification of kynurenine pathway metabolites in serum from healthy donors and patients with gastric or pancreatic cancer.

PMID:
42541923
Bibliographic data and abstract were imported from PubMed on 02 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.